Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
20 avr. 2021 08h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences....
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
03 mars 2021 06h45 HE
|
Coherus BioSciences, Inc.
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China, and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi...
Coherus Management to Present at Upcoming Investor Conferences
25 févr. 2021 08h45 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences...
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
24 févr. 2021 16h01 HE
|
Coherus BioSciences, Inc.
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with...
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
17 févr. 2021 07h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has...
Coherus Announces CFO Transition Plans
16 févr. 2021 08h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will...